Literature DB >> 19830425

Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials.

Deting Xue1, Qiang Zheng, Hang Li, Shengjun Qian, Bo Zhang, Zhijun Pan.   

Abstract

Whether selective cyclo-oxygenase-2 (COX-2) inhibitors are equally effective compared to nonselective NSAIDs for the prevention of heterotopic ossification (HO) after total hip arthroplasty (THA) is still unclear. We carried out a comprehensive search strategy, in which only randomised controlled trials were included. Two reviewers independently assessed methodological quality and extracted outcome data. Analyses were performed using Stata version 10.0. Four eligible randomised controlled trials totalling 808 patients were included. Meta-analysis results showed that no statistically significant difference was found in overall incidence of HO (RR 1.08; 95% CI 0.71-1.64), incidence of moderate severe HO (Brooker II and III) (RR 0.83; 95% CI 0.48-1.42) and any grade of Brooker classification between two groups. In summary, the selective COX-2 inhibitors are equally effective as nonselective NSAIDs for the prevention of HO after THA. Considering the gastrointestinal side effects of nonselective NSAIDs, we recommend selective COX-2 inhibitors for the prevention of HO after THA. However, future well-designed, randomised controlled trials are still needed to further confirm our results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19830425      PMCID: PMC3014496          DOI: 10.1007/s00264-009-0886-y

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  24 in total

Review 1.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

Authors:  D Moher; D J Cook; S Eastwood; I Olkin; D Rennie; D F Stroup
Journal:  Lancet       Date:  1999-11-27       Impact factor: 79.321

Review 2.  A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery.

Authors:  B C Neal; A Rodgers; T Clark; H Gray; I R Reid; L Dunn; S W MacMahon
Journal:  Acta Orthop Scand       Date:  2000-04

3.  COX-2 selective NSAID decreases bone ingrowth in vivo.

Authors:  Stuart Goodman; Ting Ma; Michael Trindade; Takashi Ikenoue; Ippe Matsuura; Neal Wong; Nora Fox; Mark Genovese; Don Regula; R Lane Smith
Journal:  J Orthop Res       Date:  2002-11       Impact factor: 3.494

4.  COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam.

Authors:  E W G Weber; R Slappendel; M E Durieux; R Dirksen; H van der Heide; M Spruit
Journal:  Eur J Anaesthesiol       Date:  2003-12       Impact factor: 4.330

5.  Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam.

Authors:  Thomas Barthel; Bernd Baumann; Ulrich Nöth; Jochen Eulert
Journal:  Acta Orthop Scand       Date:  2002-12

6.  A note on graphical presentation of estimated odds ratios from several clinical trials.

Authors:  R F Galbraith
Journal:  Stat Med       Date:  1988-08       Impact factor: 2.373

7.  The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial.

Authors:  S A Schmidt; P Kjaersgaard-Andersen; N W Pedersen; S S Kristensen; P Pedersen; J B Nielsen
Journal:  J Bone Joint Surg Am       Date:  1988-07       Impact factor: 5.284

8.  Indomethacin for 3 days is not effective as prophylaxis for heterotopic ossification after primary total hip arthroplasty.

Authors:  H J van der Heide; R T Koorevaar; B W Schreurs; A van Kampen; A Lemmens
Journal:  J Arthroplasty       Date:  1999-10       Impact factor: 4.757

9.  Ectopic ossification following total hip replacement. Incidence and a method of classification.

Authors:  A F Brooker; J W Bowerman; R A Robinson; L H Riley
Journal:  J Bone Joint Surg Am       Date:  1973-12       Impact factor: 5.284

Review 10.  Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs.

Authors:  Elham Rahme; Alan N Barkun; Viviane Adam; Marc Bardou
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

View more
  22 in total

Review 1.  Steps in the undertaking of a systematic review in orthopaedic surgery.

Authors:  Dario Sambunjak; Miljenko Franić
Journal:  Int Orthop       Date:  2011-12-24       Impact factor: 3.075

2.  Incidence of heterotopic ossification in direct anterior vs posterior approach to total hip arthroplasty: a retrospective radiographic review.

Authors:  Elizabeth A Newman; David C Holst; Daniel N Bracey; Gregory B Russell; Jason E Lang
Journal:  Int Orthop       Date:  2015-11-27       Impact factor: 3.075

3.  Acetabuloplasty with bone grafting in uncemented hip replacement for protrusion.

Authors:  Sándor-György Zuh; Ancuţa Zazgyva; István Gergely; Tudor Sorin Pop
Journal:  Int Orthop       Date:  2015-05-29       Impact factor: 3.075

4.  The efficacy of a multimodal analgesia protocol in preventing heterotopic ossification after acetabular fractures surgery.

Authors:  Liang Cheng; Hai-Tao Long; Bu-Hua Sun; Shu-Shan Zhao; Yong Zhu
Journal:  Int J Clin Pharm       Date:  2017-05-12

Review 5.  Improvement of research quality in the fields of orthopaedics and trauma: a global perspective.

Authors:  Hangama C Fayaz; Norbert Haas; James Kellam; Suthorn Bavonratanavech; Javad Parvizi; George Dyer; Tim Pohlemann; Jörg Jerosch; Karl-Josef Prommersberger; Hans Christoph Pape; Malcolm Smith; Marc Vrahas; Carsten Perka; Klaus Siebenrock; Bassem Elhassan; Christopher Moran; Jesse B Jupiter
Journal:  Int Orthop       Date:  2013-05-21       Impact factor: 3.075

Review 6.  Heterotopic Ossification Following Upper Extremity Injury.

Authors:  Shailesh Agarwal; Shawn Loder; Benjamin Levi
Journal:  Hand Clin       Date:  2017-05       Impact factor: 1.907

7.  Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac.

Authors:  Sebastian Winkler; Hans-Robert Springorum; Tobias Vaitl; Martin Handel; Sabine Barta; Victoria Kehl; Benjamin Craiovan; Joachim Grifka
Journal:  Int Orthop       Date:  2016-01-04       Impact factor: 3.075

8.  Bone mineral density is not related to heterotopic ossification after total hip arthroplasty.

Authors:  Kunihiko Okano; Kiyoshi Aoyagi; Makoto Osaki; Satoru Motokawa; Tomoko Matsumoto
Journal:  Int Orthop       Date:  2011-12-22       Impact factor: 3.075

9.  Risk factors for the development of heterotopic ossification in seriously burned adults: A National Institute on Disability, Independent Living and Rehabilitation Research burn model system database analysis.

Authors:  Benjamin Levi; Prakash Jayakumar; Avi Giladi; Jesse B Jupiter; David C Ring; Karen Kowalske; Nicole S Gibran; David Herndon; Jeffrey C Schneider; Colleen M Ryan
Journal:  J Trauma Acute Care Surg       Date:  2015-11       Impact factor: 3.313

10.  Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?

Authors:  Jaap J Brunnekreef; Paul Hoogervorst; Marieke J Ploegmakers; Wim H Rijnen; Berend W Schreurs
Journal:  Int Orthop       Date:  2013-01-29       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.